Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery. Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH. A recently developed, humanized monoclonal antibody directed against complement component C5, eculizumab (Soliris; Alexion Pharmaceuticals Inc., Cheshire, CT, USA), blocks the proinflammatory and cytolytic effects of terminal complement activation. The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eculizumab exemplifies a more extreme case. It binds human complement component C5 with high affinity but does not cross-react with rodent C5. Conventional rodent PK and pharmacology studies are therefore essentially uninformative regarding target engagement.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [53]
Citations
Cites
1 retracted
The structure of complement C3b provides insights into complement activation and regulation
Ajees, A. A., Gunasekaran, K., Volanakis, J. E., Narayana, S. V. L., Kotwal, G. J., & Murthy, H. M. K. (2006) · Nature · doi:10.1038/nature05258 · Cited by 70
RetractedHematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91481-4 · Cited by 1,437
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11367.x · Cited by 1,164
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Research works printed but not linked: 4
- Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology (Mosby-Elsevier, Philadelphia, 2006).
- Jain, R.I., Moreland, L.W., Caldwell, J.R., Rollins, S.A. & Mojcik, C.F. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 42, S77 (1999).
- Tesser, J. et al. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
- Rotoli, B. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 26, 201–207 (1989).
Cited by
Items 501–600 of 780
Şen, S., Tuncer, A., Terzi, M., Bünül, S. D., Acar, N. P., Altunrende, B., Özakbaş, S., Tütüncü, M., Uygunoğlu, U., Akman‐Demir, G., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104949 · Cited by 8
Golfinopoulou, R., Giudicelli, V., Manso, T., & Κοσσίδα, Σ. (2023) · Vaccines · doi:10.3390/vaccines11121756 · Cited by 11
“Eculizumab is a humanized IgG2–G4-kappa antibody that targets complement 5 (C5), previously established as therapy for disorders such as hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria [32].”
BackgroundCutaneous Vasculitis and Digital Ischaemia Caused by Heterozygous Gain-of-Function Mutation in C3
Omoyinmi, E., Mohamoud, I., Gilmour, K. C., Brogan, P. A., & Eleftheriou, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02524 · Cited by 8
“Eculizumab is a humanized monoclonal antibody that binds C5 and prevents assembly of the membrane attack complex (C5b-9) thereby blocking the final complement cascade and reducing uncontrolled activation of the alternative complement pathway (35).”
BackgroundNationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab
Kang, K., Moon, H., Lee, B., Jeon, M. J., Yu, E. S., Kim, D. S., Lee, S. R., Sung, H. J., Choi, C. W., Kim, B. S., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04133-z · Cited by 9
Ikeda, Z., Kamei, T., Sasaki, Y., Reynolds, M., Sakai, N., Yoshikawa, M., Tawada, M., Morishita, N., Dougan, D. R., Chen, C., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00348 · Cited by 9
Human C3 glomerulopathy provides unique insights into complement factor H–related protein function
Holers, V. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69684 · Cited by 8
Therapeutic regulation of complement in patients with renal disease – where is the promise?
Thurman, J. M. (2011) · Clinical Nephrology · doi:10.5414/cn107220 · Cited by 8
“Eculizumab is a monoclonal antibody to C5 that prevents the generation of C5a and C5b-9 [41].”
BackgroundInfluentialRiedl, M., Hofer, J., Giner, T., Rosales, A., Häffner, K., Simonetti, G. D., Walden, U., Maier, T., Heininger, D., Jeller, V., et al. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.05.009 · Cited by 8
“Prognosis in aHUS is markedly improved by blocking the terminal complement pathway with eculizumab, a monoclonal anti-C5 antibody (Rother et al., 2007; Legendre et al., 2013; Licht et al., 2015; Loirat et al., 2016).”
BackgroundLevine, T. (2019) · American Journal of Case Reports · doi:10.12659/ajcr.916424 · Cited by 8
“Eculizumab is a humanized murine monoclonal antibody that blocks formation of the terminal complement complex by binding to C5 and preventing its enzymatic cleavage to C5a and C5b [13,14].”
BackgroundParoxysmal nocturnal hemoglobinuria without GPI-anchor deficiency
Brodsky, R. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci131647 · Cited by 8
Saito, M., Harada, S., Ogasawara, R., Izumiyama, K., Mori, A., Morioka, M., & Kondo, T. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s255298 · Cited by 8
Infections in the Era of Targeted Therapies: Mapping the Road Ahead
Calabrese, L. H., Calabrese, C. M., Lenfant, T., Kirchner, E., & Strand, V. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00336 · Cited by 8
Lefranc, M., & Lefranc, G. (2024) · Immunological Reviews · doi:10.1111/imr.13399 · Cited by 9
Dixon, B. P., & Sabus, A. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13642 · Cited by 7
Future treatment for Guillain–Barré syndrome
Kuwabara, S., & Misawa, S. (2016) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12343 · Cited by 7
“Eculizumab is a humanized monoclonal antibody against complement component 5 (C5), and suppresses its cleavage into active chemotaxis mediator C5a, and attacks complex component C5b, thereby inhibiting membrane attack complex (MAC) formation.(13,14) In particular, immunohistochemical studies have shown that MAC deposi…”
BackgroundYatime, L., Merle, N. S., Hansen, A. G., Friis, N. A., Østergaard, J. A., Bjerre, M., Roumenina, L. T., Thiel, S., Kristensen, P. K., & Andersen, G. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02822 · Cited by 8
“As compared to the C5:eculizumab complex which displays affinity in the 100 pM range (29, 41), the strength of the C5:sdAb_E4 interaction is even lower (104 to 105 decrease in affinity).”
BackgroundPharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?
Can, S., Altunbaş, M. Y., & Ozen, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2388267 · Cited by 6
“This mechanism is also observed in systemic complement disorders such as atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH) [6,7].”
Jang, J. H., Han, B., Jung, J., Russo, P., & Kulasekararaj, A. G. (2025) · BioDrugs · doi:10.1007/s40259-025-00707-3 · Cited by 6
“Eculizumab is a biological medicine consisting of a humanized monoclonal antibody that targets the complement protein C5 and inhibits its activation to prevent or reduce hemolysis [1].”
Prajapati, K. P., Mittal, S., Ansari, M., Mishra, N., Mahato, O. P., Tiku, A. B., Anand, B. G., & Kar, K. (2024) · ACS Nano · doi:10.1021/acsnano.4c09522 · Cited by 6
Ladwig, P. M., & Willrich, M. A. V. (2021) · Journal of Mass Spectrometry and Advances in the Clinical Lab · doi:10.1016/j.jmsacl.2021.08.002 · Cited by 6
Exploiting the neonatal crystallizable fragment receptor to treat kidney disease
Dylewski, J. F., Haddad, G., & Blaine, J. T. (2023) · Kidney International · doi:10.1016/j.kint.2023.09.024 · Cited by 7
“74 Ravulizumab is an engineered version of eculizumab with improved FcRn recycling which extended the half-life to about 50 days.”
Learnings from over 25 years of PNH experience: The era of targeted complement inhibition
Heitlinger, E. (2013) · Blood Reviews · doi:10.1016/s0268-960x(13)00080-5 · Cited by 8
4. Paroxysmal Nocturnal Hemoglobinuria
Nishimura, J., & Kanakura, Y. (2012) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.101.1953 · Cited by 6
Marked clinical and jitter improvement after eculizumab in refractory myasthenia
Juel, V. C., Sanders, D. B., Hobson‐Webb, L. D., Massey, J. M., Guptill, J. T., O’Brien, F., Wang, J. J., & Howard, J. F. (2017) · Muscle & Nerve · doi:10.1002/mus.25620 · Cited by 6
“received eculizumab 600 mg/week for 4 weeks, 900 mg 1 week later, then maintenance eculizumab 900 mg every 2 weeks for 12 weeks.(1) MG manual muscle testing (MG-MMT)(4) and quantitative MG (QMG) scores(5) and jitter and acetylcholine”
Illingworth, A. J., Keeney, M., & Sutherland, D. R. (2016) · ASM Press eBooks · doi:10.1128/9781555818722.ch18 · Cited by 6
Complement in hemolytic anemia
Brodsky, R. A. (2015) · Hematology · doi:10.1182/asheducation.v2015.1.385.3917876 · Cited by 6
Recurrent cerebral ischaemic events in the setting of paroxysmal nocturnal haemoglobinuria
Azevedo, L., Costa, M. R., Fonseca, A. C., & Melo, T. P. E. (2016) · BMJ Case Reports · doi:10.1136/bcr-2015-213603 · Cited by 7
Effectiveness of single detachable COOK coils in closure of the patent ductus arteriosus.
Brown, S. C., Bruwer, A. D., Al-Zaghal, A., & Claassens, A. (2004) · PubMed · Cited by 6
Plasma levels of complement components C5 and C9 are associated with thrombin generation
Díaz, R. V., Munsch, G., Iglesias, M. J., Robles, A. P., Ibrahim‐Kosta, M., Nourse, J. P., Khan, E. S., Castoldi, E., Saut, N., Boland, A., et al. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.04.026 · Cited by 5
Apostolidou, E., Georgoulis, V., Leonardos, D., Kapsali, E., & Hatzimichael, E. C. (2025) · Diseases · doi:10.3390/diseases13090298 · Cited by 7
Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies
Chen, J. Y., Sanghani, N., Palmer, K., Li, Y., Lin, F., & Abbatemarco, J. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1695461 · Cited by 8
Tsaregorodtseva, T. S., Radyukhina, M. A., Ayupova, A. I., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114818 · Cited by 5
Paroxysmal nocturnal haemoglobinuria in pregnancy–a systematic review with meta analysis
Manning, J. E., Ciantar, E., Griffin, M., & Kelly, R. J. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06353-7 · Cited by 5
Kerboua, K. E., Haiba, F., & Batouche, D. D. (2016) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2016.1234485 · Cited by 5
“IgG2 fails to activate cellular immunity by Fc receptors while IgG4 does not activate complement in purpose to reduce the pro-inflammatory potential of this molecule and increase its plasma half-life to ∼11 days.([14]) Importantly, the current guidelines on eculizumab treatment prescribe the same dose regimen for all…”
BackgroundImplication de la cascade du complément dans les formes sévères de COVID-19
Benmansour, N. C., Carvelli, J., & Vivier, É. (2021) · médecine/sciences · doi:10.1051/medsci/2021021 · Cited by 6
Anliker, M., Drees, D., Loacker, L., Häfner, S., Griesmacher, A., Hoermann, G., Fux, V., Schennach, H., Hörtnagl, P., Dopler, A., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100031 · Cited by 7
Therapeutic issues in Guillain–Barré syndrome
Magy, L., & Frachet, S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2212163 · Cited by 6
“Eculizumab, a humanized monoclonal IgG2 antibody targeting the C5 complement fraction, which prevents the membrane attack complex formation (MAC) [75] has been approved for use in paroxysmal hemoglobinuria.”
BackgroundLatyshev, V. D., Таймуразовна, Ф. З., Ponomarev, R. V., Tsvetaeva, N. V., Mikhaylova, E. A., Lukina, E., & Parovichnikova, E. N. (2024) · Oncohematology · doi:10.17650/1818-8346-2024-19-1-83-91 · Cited by 5
Perisurgical induction of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria
Kurita, N., Obara, N., Fukuda, K., Nishikii, H., Sato, A., Inagawa, S., Kurokawa, T., Owada, Y., Ninomiya, H., & Chiba, S. (2013) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328360d057 · Cited by 5
(2012) · Elsevier eBooks · doi:10.1533/9781908818096.197 · Cited by 5
Brezski, R. J., & Almagro, J. C. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_4 · Cited by 9
“Decreased ADCC, ADCP, CDC IgG2/4:IgG2 sequence 118-260; IgG4 sequence 261-447 (Rother et al. 2007)”
BackgroundDrug-induced Thrombotic Microangiopathy Caused by Gemcitabine
Hasan, A. S., Jain, A. G., Naim, H., Munaf, A., & Everett, G. D. (2018) · Cureus · doi:10.7759/cureus.3088 · Cited by 5
Zipfel, P. F., & Lauer, N. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4118-2_11 · Cited by 6
Kumar, P., Chaudhary, B., Devi, S., Dubey, G., Chatterjee, A., Sharma, D., & Gupta, M. M. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100113 · Cited by 5
Pozelimab, a human monoclonal immunoglobulin for the treatment of CHAPLE disease
Kaur, M., & Misra, S. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0008 · Cited by 4
Ruthsatz, T., Wymann, S., Velkoska, E., Mansour, M., Schu, D. J., Lichtfuss, M., Rossato, P., FitzPatrick, M., Hosback, S., Dyson, A., et al. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.117191 · Cited by 4
Pour-Reza-Gholi, F., & Assadiasl, S. (2023) · Journal of Nephropharmacology · doi:10.34172/npj.2023.10630 · Cited by 4
“Considering the destructive role of C5 and MAC in the pathogenesis of PNH, some clinical trials have been conducted to evaluate the efficacy of complement inhibition in treating PNH patients (29).”
BackgroundMiyake, H., Tanabe, K., Yamaji, S., & Kihara, T. (2023) · CEN Case Reports · doi:10.1007/s13730-023-00841-3 · Cited by 4
Budylowski, P., Chau, S., Banerjee, A., Guvenc, F., Samson, R., Hu, Q., Fiddes, L. K., Seifried, L. A., Chao, G. Y. C., Buchholz, M., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300320 · Cited by 4
Antibody-mediates inhibition of human C1s and the classical complement pathway
Carroll, S., & Georgiou, G. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.01.001 · Cited by 4
Connock, M. J., Wang, D., Fry-Smith, A., & Moore, D. (2008) · Cited by 4
Cone, J., Kimmel, L. H., Zhang, Y., Johnson, K. K., Sheridan, D. L., & Tamburini, P. P. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284502 · Cited by 4
“It is important therefore to understand whether large multivalent complexes such as those described presently might have an increased potential for tissue deposition because they comprise antibodies that have been Fcengineered to eliminate or reduce their capacity to activate complement or bind to Fcγ receptors [1, 11…”
BackgroundObservation of Heavy-Chain C-Terminal Des-GK Truncation in Recombinant and Human Endogenous IgG4
Shah, B., Zhu, Y., Wypych, J., & Zhang, Z. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.05.005 · Cited by 5
Anderson, M., MAGRO, C. M. J., & Belmont, M. H. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000996 · Cited by 4
Microangiopatías trombóticas en la unidad de cuidados intensivos
Assis, F. M. C., Ortíz, G., Fernández, M. G., Córdoba, J. P., Yepes, D., A., M. A. G., Durán, J., & Rojas-Suárez, J. A. (2017) · Acta Colombiana de Cuidado Intensivo · doi:10.1016/j.acci.2017.02.003 · Cited by 4
The wonderful story of monoclonal antibodies
Béné, M. C. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13006 · Cited by 5
A modern view on the complement system
Shakhidzhanov, S. S., Filippova, A. E., Butilin, A. A., & Ataullakhanov, F. I. (2019) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2019-18-3-130-144 · Cited by 6
A novel approach to immunoapheresis of C3a/C3 and proteomic identification of associates
Winnicki, W., Pichler, P., Mechtler, K., Imre, R., Steinmacher, I., Sengölge, G., Gerges, D., Beilhack, G. F., & Wagner, L. (2019) · PeerJ · doi:10.7717/peerj.8218 · Cited by 4
“There are currently five therapeutics targeted against complement factors on the market, which are approved for four indications (hereditary angioedema, PNH (Rother et al., 2007), aHUS (Fakhouri & Fremeaux-Bacchi, 2013) and generalized myasthenia gravis (Ricklin et al., 2018)) and numerous drug candidates have been (D…”
BackgroundInfluentialObservation of Heavy-Chain C-Terminal Amidation in Human Endogenous IgG
Shah, B., Li, M., Wypych, J., Joubert, M. K., & Zhang, Z. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.06.012 · Cited by 4
Paroxysmal Nocturnal Hemoglobinuria: Diagnostic Challenges in Pediatric Patient
Krishnaprasadh, D., Kaminecki, I., Perl, A. S., & Teitelbaum, J. E. (2019) · Case Reports in Pediatrics · doi:10.1155/2019/4930494 · Cited by 4
“Eculizumab, a monoclonal antibody, is a terminal complement inhibitor and reduces intravascular hemolysis and risk of thrombosis [11, 12].”
BackgroundGeneral Principles of Immunotherapy in Neurological Diseases
Rommer, P. S., Hecker, M., Zrzavy, T., Boxberger, N., & Zettl, U. K. (2019) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-19515-1_12 · Cited by 5
Peptide‐Fc Fusion Therapeutics: Applications and Challenges
Huang, C., & Swanson, R. V. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch8 · Cited by 4
Novel treatments for myasthenia gravis
Narayanaswami, P., Verity, R., & Vissing, J. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.08.001 · Cited by 4
Wang, Y., Huang, C., Cai, G., Andreatta, M., Kurum, A., Zhao, Y., Feng, B., Gao, M., Carmona, S. J., Zhou, Z., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117035 · Cited by 4
Boshkos, M. C., Fives, K. R., Phrathep, D. D., Healey, K. D., & Patel, M. (2023) · Cureus · doi:10.7759/cureus.36240 · Cited by 3
“Complement inhibitors (CI) have revolutionized treatment modalities for PNH patients resulting in decreased rates of thrombosis, renal failure, and overall mortality [4].”
BackgroundThe role of the complement system in cancer etiology and management
Sonderegger, S., Manzanero, S., Woodruff, T. M., Farouqa, J., Nabizadeh, J., Panagides, N., & Rolfe, B. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87763-3.00012-5 · Cited by 3
An evaluation of pozelimab for the treatment of CHAPLE disease
Can, S., Altunbaş, M. Y., & Ozen, A. O. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2438740 · Cited by 3
“More critically, the hyperactivation of the complement system in CHAPLE disease can cross-activate the coagulation cascade, a phenomenon also seen in other complement-mediated disorders such as atypical hemolytic uremic syndrome (aHUS) [10] and paroxysmal nocturnal hemoglo-binuria (PNH) [11].”
Other Approved Therapeutic Monoclonal Antibodies
Baldo, B. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-30472-4_4 · Cited by 3
Nieto‐Ríos, J. F., Serna-Higuita, L. M., Botero, E. C., Ocampo-Kohn, C., Aristizábal-Alzate, A., Zuluaga-Quintero, M., & Zuluaga-Valencia, G. A. (2015) · Nefrología · doi:10.1016/j.nefro.2015.07.008 · Cited by 3
Myasthenia Gravis – A Review of Current Therapeutic Options
Jacob, S. (2018) · European Neurological Review · doi:10.17925/enr.2018.13.2.86 · Cited by 4
“Blockade of the complement pathway at C5 halts the production of the pro-inflammatory and pro-thrombotic C5a and C5b molecules, which are important for inflammatory cell chemotaxis and activation of the MAC.(72) Furthermore, this does not impair the immunoprotective and immunoregulatory functions of the proximal casca…”
BackgroundHow Structures of Complement Complexes Guide Therapeutic Design
Bickel, J. K., Voisin, T. B., Tate, E. W., & Bubeck, D. (2020) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-58971-4_7 · Cited by 3
A Splice Site Mutation Associated with Congenital CD59 Deficiency
Chai, J. N., Azad, A. K., Kuan, K., Guo, X., & Wang, Y. (2022) · Hematology Reports · doi:10.3390/hematolrep14020025 · Cited by 3
Antimicrobial activity of the complement system
Egorova, E. V., Krenev, I. A., Oborin, N. N., & Николаевич, Б. М. (2023) · Medical academic journal · doi:10.17816/maj322841 · Cited by 3
Ryder, S. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3382 · Cited by 3
“29,30 In female NZB/WF1 mice administration of BB5.”
InfluentialWei, X., Liu, X., Yu, Y., Xie, W., Luo, W., Tu, Y., Bu, S., & Guo, G. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1404725 · Cited by 3
Farley, K. A., Che, Y., Lira, R., Jones, P., Papaioannou, N., Hayward, M. M., Flanagan, M. E., Langille, J., Liang, S. X., Pierce, B. S., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00316 · Cited by 3
Alfonso‐González, L., Vega, M. C., & Fernández, F. J. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70054 · Cited by 2
“In contrast, eculizumab, which specifically targets the TP (Rother et al., 2007), was included as a negative control without expecting any beneficial effect on the AP.”
Ischemic Stroke Presenting as the First Symptom in a Setting of Paroxysmal Nocturnal Hemoglobinuria
Ahsan, M. J., Ishtiaq, R., & Ishtiaq, D. (2017) · Cureus · doi:10.7759/cureus.1439 · Cited by 3
“This drug binds to C5 inhibiting terminal complement system and blocking the formation of membrane attack complex [8].”
BackgroundBoackle, S. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47927-1.00016-5 · Cited by 4
Singh, N., & Khandey, P. (2018) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/14196_24 · Cited by 5
Membranoproliferative and C3-Mediated GN in Children
Licht, C. P. B., Riedl, M., Pickering, M. C., & Braun, M. (2015) · Springer eBooks · doi:10.1007/978-3-642-27843-3_29-1 · Cited by 7
Antwi-Baffour, S. S., Kyeremeh, R., Adjei, J. K., Aryeh, C., & Kpentey, G. (2016) · Autoimmunity Highlights · doi:10.1007/s13317-016-0078-x · Cited by 4
Complement factors (H) into thrombosis
Holinstat, M. A. (2017) · Blood · doi:10.1182/blood-2017-01-761528 · Cited by 3
“It is now appreciated that aHUS can present in adults as well as in children and can be treated with anticomplement therapy such as eculizumab when properly diagnosed.(7) However, the underlyingmechanismbywhichFHmutations result in TMAs is not well understood.”
BackgroundPrudnikova, E. Y., Poroshin, G. N., Kudina, N. K., Lyagoskin, I. V., Sazonova, E. V., Вишневский, А. Ю., & Abbasova, S. G. (2016) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2016-4-6-54-71 · Cited by 3
Magnetic bead based assays for complement component C5
DiScipio, R. G., & Schraufstätter, I. U. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.07.010 · Cited by 3
NHDL, a recombinant V L /V H hybrid antibody control for IgG2/4 antibodies
Lau, C., McAdam, M. B., Bergseth, G., Grevys, A., Bruun, J., Ludviksen, J. K., Fure, H., Espevik, T., Moen, A. R., Andersen, J. T., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1686319 · Cited by 4
Ask the Hematologist: How Do I Diagnose and Treat PNH?
Parker, C. (2008) · The Hematologist · doi:10.1182/hem.v5.3.6089 · Cited by 3
Monoclonal Antibodies as Therapeutic Agents
Khan, M. M. (2008) · Springer eBooks · doi:10.1007/978-0-387-77976-8_5 · Cited by 4
Hemolytic uremic syndrome caused by E. coli O157 infection
Bystrom, P., Beck, R. J., & Prahlow, J. A. (2017) · Forensic Science Medicine and Pathology · doi:10.1007/s12024-017-9852-y · Cited by 3
“Eculizumab works by inhibiting the complement cascade at the step of C5 cleavage; this is thought to inhibit the recruitment of inflammatory cells and thus attenuate damage to the vascular endothelium [12].”
BackgroundMallillin, M. C., Silva, D. A., Miller, N. A., Zhao, S., Salami, M., Löbenberg, R., & Davies, N. M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070824 · Cited by 2
“Human dose selection relied on ex vivo human assays and PK/PD modelling anchored in non-human primate data, where cross-reactivity exists [53].”
Wang, T., Wang, Y., Wang, Y., Wang, X., Cheng, X., Tan, Q., Zhu, T., Teng, X., Huang, H., & Shen, Z. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-1113 · Cited by 4
Amen, A., Thielens, N. M., Dumestre‐Pérard, C., & Clavarino, G. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102638 · Cited by 2
Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition
Kelly, R. J., Holt, M., & Szer, J. (2025) · Drugs · doi:10.1007/s40265-025-02235-4 · Cited by 7
“Eculizumab is a 148-kilodalton molecule composed of murine complementary determining regions within human germline framework regions and immunoglobulin (Ig)G2 and IgG4 heavy chain constant regions [47].”
Redox Regulation of Complement Pathway Activation in Aging and Related Diseases
Ferdowsi, S., Arjuna, S., Sudharshan, S. J., & Zennadi, R. (2025) · Antioxidants · doi:10.3390/antiox15010029 · Cited by 3
“…the first anti-complement agent, eculizumab, which is a monoclonal antibody that interferes with the cleavage of the C5 complement component [239], have shown its potential impact for treating paroxysmal nocturnal hemoglobinuria (PNH) [240–242] and atypical hemolytic uremic syndrome (aHUS) [243].”
Design of miniprotein inhibitors targeting complement C9 to block membrane attack complex assembly
Li, M., Wang, N., Fu, X., Wei, G., Zhang, Z., Yu, Y., Xue, T., Zhao, Y., Pan, J., Dongfeng, W. A. N. G., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70667-x · Cited by 4
A Universal Buffer System for Native LC–MS Analysis of Antibody-Based Therapeutics
Vosper, K. R., Davis, B. T. V., Saraya, J. S., O’Flaherty, D. K., Vėlyvis, A., & Vahidi, S. (2026) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.6c00028 · Cited by 2
The evolving landscape of complement therapeutics in rheumatology
Holers, V. M. (2026) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2026.02.020 · Cited by 3
Schrezenmeier, H., Bettelheim, P., Panse, J., Schubert, J. E. A., Höchsmann, B., Röth, A., & Nebe, T. (2012) · Journal of Laboratory Medicine · doi:10.1515/jlm.2011.060.et · Cited by 2
Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Burns, E. A., Anand, K., Acosta, G. J., Irani, M., Chung, B. M., Maiti, A., Ibrahim, I., & Rice, L. (2019) · Case Reports in Hematology · doi:10.1155/2019/3146965 · Cited by 2
“*e only FDA approved therapy is eculizumab, a humanized monoclonal antibody that prevents the cytolytic and proinflammatory effects of the terminal complement system by acting against the C5 component of the complement cascade [2].”
BackgroundTavasoli, A., Nakhaie, S., Zafaranloo, N., Hoseini, R., Otukesh, H., & Sobouti, B. (2021) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.35.91 · Cited by 2
Metadata
- Authors
- Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L.
- Affiliations
- Alexion Pharmaceuticals (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Rother, Russell P
- Venue
- Nature Biotechnology
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 1256-1264
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2004265876
- Cited by
- 778
- References
- 88
- Citations by year
- 2026: 34 · 2025: 38 · 2024: 43 · 2023: 58 · 2022: 34 · 2021: 47 · 2020: 59 · 2019: 49 · 2018: 42 · 2017: 52 · 2016: 60 · 2015: 39 · 2014: 41 · 2013: 38 · 2012: 43
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2007-12-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, paroxysmal nocturnal hemoglobinuria, complement inhibition, complement component C5, CD59, intravascular hemolysis, monoclonal antibodies, glycosylphosphatidylinositol deficiency, terminal complement activation, drug development
- MeSH terms
- Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Complement C5, Drug Evaluation, Preclinical, Hemoglobinuria, Paroxysmal, Humans, Drug Design, Protein Engineering, Drug Approval, Complement Inactivating Agents, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.